In a hot, dusty shanty town in the Indian city of Kolkata, a group of barefoot ‘street children’ rush to greet an ambulance.

Talking to: Martin Edlund, CEO of Malaria No More.

Engineers spent two decades developing a new generation of contact lenses, Dailies Total1, to address the issue of discomfort users experience with existing silicone hydrogel lenses. Dailies Total1 feature a revolutionary water gradient technology, enabling the lens to transition to an ultra-soft surface gel layer made up of more than 80% water, nearly the same as the surface of the eye, which helps minimize friction with the delicate tissues of the eye.

The majority of Europeans can’t identify the warning signs of heart failure, a life threatening disease, which affects one in five people in the region.

Two years ago, the global community convened in London to hold a significant international meeting on neglected tropical diseases (NTDs). These commitments are now known as the London Declaration. On April 2, this group of partners came together once more to discuss progress toward the goals outlined in 2012.

Efforts to improve health care in Africa take on many forms, from broadening access to high-quality modern medicines, to bolstering health care systems.

Novartis is investing in thermal energy storage to minimize fuel costs and reduce the carbon footprint of new buildings.

Novartis is working to tackle the problem of counterfeit drugs, which are a threat to patient health.

Patients with glaucoma, which affects 60 million people worldwide, can lose up to 40 percent of their sight before they begin to notice any change in vision.

Novartis is working across Africa to build research capacity.

Raising a child with a rare disease can feel overwhelming and isolating, but many parents end up being extremely proud of their children’s achievements.

Novartis has been selected as a finalist for the 2013 PR News’ CSR Awards in the category “Social Good” for its Arogya Parivar initiative, one of the company’s pioneering new business approaches to sustainably deliver healthcare to more people, particularly in the developing world.

Novartis is proud to have achieved Silver Class status in this year’s edition of the RobecoSAM “Sustainability Yearbook” for our excellent sustainability performance.

Parents and doctors can help children understand rare diseases like TSC and SJIA with the help of cartoon dogs and comic book superheroes.

Novartis Corporate Responsibility News is a quarterly e-newsletter that will keep you updated on our CR programs and initiatives. Subscribe if you would like to receive the e-newsletter by email.

Novartis is ranked among the top 20 most sustainable companies with respect to reducing carbon emission between 2005 and 2012. Of 100 companies analyzed, Novartis ranked #18 across all industries, #4 in the healthcare sector and #1 in Switzerland. This new ranking, conducted by Climate Counts, a US non-profit founded to fight climate change in cooperation with the Center for Sustainable Organizations, evaluated whether greenhouse gas reductions by companies were sufficient to achieve the overall goal of limiting global warming to 2 degrees Celsius above pre-industrial levels.

Inclusion in the 2014 index acknowledges Novartis leadership in key areas of corporate responsibility. Companies named to the Global 100 are recognized as the top overall sustainability performers in their respective industries.

Novartis was honored with the first ever "Scrip Award for Best Advance in an Emerging Market" at the 9th Annual SCRIP awards, held in London on November 21. Novartis won for its Jian Kang Kuai Che healthcare project in China, which works to improve healthcare conditions in rural Xinjiang through educational programs in schools and by recruiting and training healthcare workers.

Africa Day at Novartis highlights the continent’s healthcare needs and efforts to address them.

At its annual symposium, the Novartis Foundation announced that it will implement a new strategy aimed at helping eliminate leprosy. Based on the consensus reached by a group of leading experts earlier this year, the strategy focuses on interrupting leprosy transmission through early diagnosis and treatment, contact tracing of former patients, diagnostic tools and strict surveillance and response.

Novartis and collaborators have discovered a new malaria drug target and a new compound class with potential to prevent, block and treat malaria. This is the third new class of malaria compounds discovered by Novartis scientists within the last five years. The findings, published in Nature, advance the Novartis goal to help eliminate malaria.

What does it take to eliminate a disease? And at the very least, how do we better control diseases so that more people have an improved chance at a long, healthy life. This year’s Novartis Foundation symposium invites esteemed speakers and experts to discuss these questions. Watch the live webcast on 29 November.

Patients with multiple sclerosis, an autoimmune disease that affects 2.5 million worldwide, lose brain volume three to five times faster than people without the disease.

Morning is the most challenging time of day for many patients with COPD, who may have shortness of breath, coughing and difficulty getting ready.

In recognition of Novartis' significant on-going contributions to malaria control and elimination, the company has been honored with the Global Corporate Citizenship Award at the Malaria No More International Honors annual benefit.

The World Forum for Ethics in Business (WFEB) has awarded Novartis the Ethics in Business Award in the Outstanding Corporation category.

Basel, November 11, 2013 - Novartis announced a definitive agreement to divest its blood transfusion diagnostics unit to Grifols for USD 1.675 billion. This transaction, requiring customary regulatory approvals, is expected to be completed in the first half of 2014.

For the third consecutive year, Novartis remains in the STOXX Global ESG Leaders indices – comprising the leading global companies in terms of ESG (environmental, social and governance) performance.

More than 125 million people globally live with psoriasis, a chronic autoimmune disease that causes red, scaly patches to appear on the skin.

The Top 25 World’s Best Multinational Workplaces is the world’s largest annual study of workplace excellence, identifying the top 25 best multinationals in terms of workplace culture.

The incidence of leprosy, an infectious disease that causes lumps and skin sores, has decreased by roughly 95%, but 233,000 new cases were reported in 2012.

US Pharmaceutical Division chosen for the magazine’s 2013 list of best employers for mothers.

Professor Klaus M. Leisinger is stepping down as Chairman of the Board of the Novartis Foundation for Sustainable Development (NFSD). Dr. Ann Aerts was named Head of the NFSD earlier this year and runs the foundation. Dr. Andrin Oswald, Division Head, Novartis Vaccines and Diagnostics and member of the Executive Committee of Novartis (ECN) will take an additional role as Chairman of the Board overseeing the NFSD.

Malaria programs in sub-Saharan Africa are making progress by using insecticide-treated nets, diagnostic testing and Artemisinin-based Combination Therapy.

More than 1.5 million healthcare workers, including nurses and birthing attendants, are needed in Africa. The continent has 24% of the world’s disease burden.

Joe Jimenez was nominated along with 20 other CEOs from global companies, NGOs and governmental organizations. CR Magazine has awarded the Responsible CEO of the Year Award since 2008. It is presented to CEOs who, during the previous year, put themselves at personal and professional risk in order to deliver on corporate responsibility promises. The five winners will be announced during the COMMIT!Forum Awards Dinner in New York City on Wednesday, October 9.

Acute heart failure (AHF) is a condition where the heart cannot pump enough blood around the body. Each year 3.5 million AHF episodes occur in the US and EU.

What does a career in science look like? How do entrepreneurs develop new biotechnology products? What sort of opportunities are there in the pharmaceutical industry? These were the questions foremost in participants’ minds as the 2013 International BioCamp reached its third and final day at the Novartis headquarters campus in Basel, Switzerland.

Sixty of the world’s most talented science students from around the world arrive in Basel next week for the Novartis BioCamp, a three-day exploration of some of the biggest challenges and opportunities in the biotech and healthcare industries.

The standard recognizes organizations that encourage healthy lifestyles and provide employees with cancer prevention, detection, and treatment programs.

Malaria No More held its annual Malaria Champions Breakfast in Washington DC yesterday, where attendees gathered to honor those who have made a difference in the fight against malaria.

By improving access to healthcare in remote areas of developing countries, SMS for Life is making a real difference in the lives of people with malaria and other diseases.

Following successful pilots in India, China, France and Latin America, Novartis Responsible Procurement went global on April 1, 2013.

Novartis and Malaria No More, a leading global charity determined to end malaria deaths, announced today that they are joining forces on the Power of One campaign to help close the treatment gap and accelerate progress in the fight against malaria.

Novartis announced today the compensation for the incoming Chairman of the Board, starting August 1, 2013, as well as the pro-rated compensation for the current Chairman ad-interim. This new disclosure ahead of the 2013 Annual Report reflects the commitment to greater transparency by the Board of Directors and the company.

Watch this trailer that pulls from all six films to introduce you to six children from around the world each facing a complex reality of healthcare.

This video is one in a series produced by filmmaker Martin Bell to accompany photography by Mary Ellen Mark as part of the Novartis Annual Report 2012. Novartis commissioned this series which is meant to capture the diverse experiences of children in various settings, demonstrating the complex realities of global healthcare.

Basel, Switzerland/Cambridge, MA, February 28, 2013 - Novartis today announced that it has launched an effort to eliminate rheumatic heart disease in Zambia in collaboration with the Lusaka University Teaching Hospital (UTH), the Ministry of Health in Zambia, the Pan-African Cardiology Society and Massachusetts General Hospital (MGH).

Novartis ranked top pharmaceutical company in Fortune's World's Most Admired Companies 2013

Novartis recognized by MIT Technology Review in its annual 50 Disruptive Companies list as one of the world's most innovative companies.

This annual special feature identifies and profiles 10 therapeutic pipeline categories covering pharma, biopharmaceutical and biotech companies as chosen by Med Ad News editors.

What do you tell a team that has failed?

The campaign is a Solutions Initiative of the United Nations Sustainable Development Solutions Network.

Group net sales up 2% in constant currencies[1] (cc) in fourth quarter despite patent expirations; flat (cc) over full year

BASEL – When it comes to health care, all stakeholders – patients, service providers, pharmaceutical companies, and governments – know that something needs to change.

Novartis advances goals set as part of a coordinated, international effort to eliminate or control 10 neglected tropical diseases (NTDs).

"Being in the Next Generation Scientist program is the best thing that could happen to you. It will change the way you do research and how you communicate your research. It's awesome."

What's the best advice you've ever been given? In the first clip for Fast Company's "30 Second MBA" video series, Novartis CEO Joe Jimenez shares his most valuable feedback and how he used this advice to turn an unexpected career move into a learning experience.

The annual symposium, held on December 4, gathered experts from four continents in Basel to discuss experiences and perspectives related to psychosocial support for Africa's children.

Event gives actors in the field the opportunity to assess psychosocial approaches and discuss various interventions that strive to ensure mental health and wellbeing for Africa's children.

Novartis has been awarded two of the prestigious SCRIP Awards for excellence in innovation and research and development (R&D). The annual awards event celebrates industry achievements in a number of categories and are considered the premier awards for the global biopharmaceuticals industry.

What will the future of health and healthcare look like? In a joint series of blog posts by the World Economic Forum's Strategic Foresight and Health teams, a number of leading voices will present their own visions for the future. Contributions are linked to the Scenarios for Sustainable Health Systems project, the Workplace Wellness Alliance and the Healthy Living Initiative. In the following post, Joseph Jimenez, Chief Executive Officer of Novartis, will share his perspective on the future of health.

Basel, November 9, 2012 - Novartis announced today that Marjorie Yang has decided not to seek re-election to the Novartis Board of Directors at the Novartis Annual General Meeting in 2013. Ms. Yang joined the Novartis Board in 2007 and her current term is ending in 2013.

Novartis R&D Day 2012 held on November 8th in Cambridge, MA, (USA) is an Investor event with senior Novartis executives discussing developments in research and development (R&D) across its divisions including Oncology and Pharmaceuticals.

Singapore, October 31, 2012 - Novartis announced today the construction of a new state-of-the-art biotechnology production site in Singapore with an investment valued at over USD 500 million. The new facility will focus on drug substance manufacturing based on cell culture technology. It will be co-located with the pharmaceutical production site based in Tuas, Singapore. In the future, Singapore is expected to be a technological competence center for both biotechnology and pharmaceutical manufacturing at Novartis.

Novartis is a founding member of WIPO Re:Search, a consortium established to accelerate discovery and development of medicines, vaccines and diagnostics for neglected tropical diseases.

Novartis is the greenest healthcare company worldwide

Novartis confirms its confidence in the safety and efficacy of its seasonal influenza vaccines Agrippal® and Fluad® manufactured in Italy. Patient safety is of the highest priority to Novartis.

Novartis confirms its confidence in the safety and efficacy of its seasonal influenza vaccines Agrippal® and Fluad® manufactured in Italy. Patient safety is of the highest priority to Novartis.

Read about global development post 2015 in the Novartis Foundation for Sustainable Development's latest newsletter

People around the world living with advanced breast cancer face many uncertainties and unanswered questions about their diagnosis. Listen as top physicians Dr. Mariana Chavez MacGregor, Dr. Jennifer Litton and Dr. Joyce O'Shaughnessy answer common questions about life with the disease and how it differs from the earlier stages of breast cancer.

Episode 1 of the Each Voice Counts talk show series, "The Women: Part 1" features four women sharing their stories of life with advanced breast cancer. Each Voice Counts is part of the Count Us, Know Us, Join Us program, the mission of which is to recognize those living with advanced breast cancer, their caregivers, supporters, friends and family members. We invite you to join us in supporting this community to reinforce that they do count.

Novartis is the most admired pharma company for the fourth straight year; Biogen Idec and Shire are first-time winners in the biotech and specialty categories.

Novartis brand ranks no. 39 globally and no. 2 in Switzerland

Novartis Pharma US named one of the best employers for working mothers.

Novartis ranked no. 11 on Science's Top 20 Employers list

Novartis named one of the top 50 most attractive employers worldwide for engineering students by Universum.

The UN Millennium Development Goals (MDG) Report 2011 gives grounds for optimism: lives have been saved; poverty has declined; and child mortality has been reduced. Yet in spite of these poverty alleviation efforts over 2.5 billion people continue to live on USD 2 or less a day.

On August 20, Sandoz and its subsidiary 1A Pharma announced its support for an innovative initiative by the Zambian government. Called Health Shops, this initiative will allow Sandoz to supply its high-quality, affordable medicines to independently owned and operated rural stores, which are the only healthcare providers in the rural communities of the country

Novartis International BioCamp highlights global R&D reach to meet patient needs in emerging markets

"Journey of Chronic Myeloid Leukemia" is the story of a fatal cancer that has been transformed into a chronic condition. CML is now considered the model for targeted therapy in hematology and oncology, as successful treatment has provided hope and inspiration for a number of other diseases.

Novartis ranked most popular employer in healthcare by Swiss students in Swiss Graduate Barometer

This week, the Supreme Court in India will hear arguments over whether the government had the right to deny a patent to Novartis for its Gleevec cancer medication. The case has focused attention on the contentious interplay between intellectual property rights and access to medicines by the economically disadvantaged. Novartis wants a patent based on a new form of its drug, which would offer a 20-year extension.

Chapter 5 of the six chapter video series highlighting the significant medical advances throughout the past decade in the treatment of gastrointestinal stromal tumors. GIST is a rare and life-threatening cancer of the gastrointestinal tract.

This three-minute video features Joe Jimenez reporting the Novartis results for the second quarter of 2012. He reviews the performance, highlights progress in innovation, and summarizes productivity and remediation of quality issues.

Novartis second quarter results enhance future growth prospects with eight significant regulatory milestones; on track to deliver 2012 outlook.

Novartis enters the list of the 50 preferred employers among European Engineering/IT students.

Novartis named the most transparent large healthcare company by Transparency International.

The Novartis Malaria Initiative is convening global experts from education, government, community health and economics to share best practices and empower local African communities to deliver sustainable malaria healthcare. Roll Back Malaria, the World Health Organization, World Bank and the African Leaders Malaria Alliance are highlighting the urgent need to ensure malaria remains a priority in the current economic climate.

Novartis wins Ethical Corporation Award for Best Corporate/NGO Partnership for SMS for Life

The results of the Swiss Student Survey reveal how students perceive organizations as employers in Switzerland.

Think you know Africa? Take another look. New healthcare problems are on the rise, though old issues still exist. How can we improve healthcare in Africa?

Growing demand and the cost of health care are stretching the budgets not just in Massachusetts, but all over the world. Governments everywhere are faced with a stark choice: leave the health care system as it is and face rising taxes and declining quality of care, or start to do things differently.

Novartis works to expand scientific and clinical capability in Africa and emerging countries. The result is mutually beneficial: Novartis gains insight into diseases in these areas, and the scientists gain connections and learn about Novartis research activities.

In the past, fast-spreading diseases were the continent's greatest threat—malaria, tuberculosis, HIV, measles, diarrhea, polio and other communicable diseases. These problems remain real and serious. But today, Africa's future may depend even more on battling chronic diseases that aren't spread between people, such as cancer, diabetes and cardiovascular disease.

Africa is on the rise. The evidence is everywhere. In a 2011 report, the World Bank declared that "Africa could be on the brink of an economic take-off." The World Health Organization (WHO) 2011 African Regional Health Report revealed that Africa has made significant progress in the battle against many communicable diseases, including river blindness, malaria, leprosy and measles, among others.

In May 2000, The Economist ran a cover story on Africa under the headline, "The Hopeless Continent." The article detailed violence and disease ravaging the region -- the cover pictured a fighter with a weapon on his shoulder framed by an African map.

Novartis has reached a significant milestone: 500 million Novartis antimalarial treatments have been delivered - without profit - to endemic countries in Africa since 2001.

The Novartis Foundation for Sustainable Development, together with CIOMAL Foundation convened an experts' meeting on innovative solutions to tackling the last mile of leprosy on 31 May 2012 in Geneva.

SMS for Life has been selected as the Laureate in the Innovation IT category of the 2012 Computerworld Honors Program. This award recognizes organizations that promote and advance the public welfare, benefit society and change the world for the better through a visionary application of IT.

Novartis again ranked as a top sustainability performer.

Novartis again among top 20 companies globally climbing one spot to No. 17.

This year's Pharm Exec 50 shows an industry whose growth has slowed to a crawl in the face of patent expirations, aggressive payers, and a tough environment for approvals.

As a healthcare company, Novartis recognizes that employees are an integral part of the company's success and a healthy workforce underpins business growth. The "Be Healthy" initiative, first introduced in 2011, has expanded to include all Novartis associates across 140 countries.

Bowen Craggs ranks Novartis No.8 in its 6th annual index of corporate web effectiveness, making it the second healthcare company on the list.

Novartis named #3 Most Valuable Swiss Brand 2012 by Interbrand/Bilanz with a brand value of CHF 6.8 billion.

Novartis has signed a definitive agreement to acquire specialty dermatology generics company Fougera Pharmaceuticals. Under the terms of the agreement, Novartis will acquire the business, which is based in Melville, New York, for USD 1.525 billion in an all-cash transaction.

Pharmaceuticals and Alcon performed strongly in the first quarter; overall Group results impacted by expected challenges

Leo and Kya are very good friends. Kya is from Africa, and one day, she was telling Leo about malaria in Africa ... Help raise awareness, educate your children and join the fight against malaria!

What if questions have always driven human progress. With today's health challenges, medical progress is more important than ever.

A target of 300 endocrinologists seems pretty specific. And small. After all, health headlines often focus on broad issues, like the 78 million obese adults or the 26 million Americans with diabetes.

Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1,000 human cancer cell lines used in drug research and development. Results of the collaboration, published in the journal Nature and released in advance online today[1], may allow scientists around the world to use this information to improve cancer clinical trial design and further cancer research.

Novartis ranked as one of the "Global 500 most valuable brands" and one of the top brands in the pharmaceutical/healthcare sector.

Mr. Jimenez was recognized for his commitment and engagement in Novartis Diversity & Inclusion initiatives.

Novartis again ranked top pharmaceutical company in Fortune's World's Most Admired Companies 2012

From pioneering Novartis medicines used by patients worldwide to treat rare forms of cancer to potential medical breakthroughs now undergoing clinical testing, our commitment to rare diseases has never been stronger. Underscoring that commitment, Novartis headquarters in Basel, Switzerland, will host the RE(ACT) Congress, the first international congress on research of rare and orphan diseases, from February 29 to March 2.

One child dies from malaria every minute, so a child-friendly medicine against the disease is critical. Novartis and MMV began working together in 2003 to develop the first pediatric formulation for an artemisinin combination therapy (ACT) against malaria.

In 2009, Novartis and MMV launched the first child friendly artemisinin-combination therapy (ACT), meeting the calls from UNICEF and the WHO for age-appropriate medicines. Three years after launch, deliveries of this child-friendly antimalarial hit the 100 million mark.

Novartis CEO Joseph Jimenez explains the company's commitment to fighting leprosy and why we need continued focus to eliminate the disease.

New solutions developed by university teams could help manage the growing global problem of noncommunicable diseases (NCDs) such as asthma, diabetes, stroke and cancer. These innovations were part of the NCD Challenge, sponsored by IBM and Novartis.

Novartis announced today that it will extend its collaboration with the World Health Organization and others to end leprosy.

Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011.

"SMS for Life" uses SMS and web based technology to expand access to medicines in the most remote areas of the world. After Tanzania and Ghana, "SMS for Life" is being implemented in Kenya and beyond antimalarials, RDTs, bed nets, antibiotics or patient surveillance data can now also be monitored.

The Becoming Christopher video trailer tells the fictional story of Christopher Morgan, a 22-year-old fictional character with cystic fibrosis, on his journey to adulthood.

Malaria remains a complex and multi-faceted problem in sub-Saharan Africa. Professor Rodriguez, Harvard University, Professor Coll-Seck, Exec. Dir. Roll Back Malaria, and Agnes Akoth, head nurse, Kombewa Clinic in Kenya, look more closely at the impact of malaria in Africa, and examine the journey Novartis undertook to apply innovation and make global access possible for patients of all backgrounds, in all locations.

In December, 2011 in Basel, the 16th annual symposium of the Novartis Foundation for Sustainable Development (NFSD) discussed the potential of Information and Communication Technologies (ICT) for democratization and development.

The rise of new media has sparked a real knowledge revolution – this is the conclusion of the annual symposium of the Novartis Foundation for Sustainable Development (NFSD), attended by around 500 participants on 2 December 2011, on the topic of "New media: drivers of democratization and development?"

Experts analyze how e-health applications improve access to quality healthcare and help contribute to achieving the health-related Millennium Development Goals. The symposium discusses the role of social media platforms in the Arab Spring and the impact of mobile phone penetration into the African continent. The annual Novartis Foundation symposium provides an important platform for dialogue on development policy issues.

See how scientists at the Novartis Institutes for BioMedical Research, have embraced a new way of thinking about disease that looks at the role of molecular pathways.

In 2001, Novartis AG and the World Health Organization (WHO) unveiled a unique 10-year alliance to provide a breakthrough medicine against malaria - without profit - for use by public health systems in developing countries.

Novartis and collaborators discover new class of antimalarial compounds with potential to both prevent and treat malaria infections.

Novartis received three 2011 Scrip Awards: Pharma Company of the Year, Best New Drug and Executive of the Year.

Novartis ranks no. 34 on the global list of Newsweek's 2011 "Green Rankings." For the first time this year, Newsweek expanded its "Green Rankings" to analyze the green score of the 100 biggest companies worldwide.

Novartis ranks #6 in the "Sustainable Performance Leaders in Pharmaceuticals" list released by JustMeans.

Novartis ranks #25 in Fortune's 2011 "Global Top Companies for Leaders" list for the quality of its leadership practices.

Novartis is named "Most Admired Pharmaceutical Company" by MedAdNews.

These global awards recognize game-changing innovations that break with conventional ideas or processes, go beyond marginal improvements and have a wide impact in their field. Led by Novartis, in partnership with IBM, Vodafone, the Ministry of Health in Tanzania, and under the umbrella of the Roll Back Malaria Partnership, SMS for Life harnesses everyday technology to improve access to essential malaria medicines in rural areas. Since rolling out nationally across Tanzania in April 2011, the program has expanded to Ghana and Kenya.

Novartis was ranked the most valuable healthcare brand in Europe (no. 20) and the third most valuable worldwide (no. 54) in the annual "eurobrand" rankings published by the European Brand Institute, Europe's leading research institute for intangible assets.

Novartis is named the "Pharmaceutical Company of the Year" by MedAdNews.

Joseph Jimenez, CEO of Novartis, talks about how Novartis Group Company associates across 32 countries are participating in a new Novartis health and well-being initiative during the first Novartis Be Healthy Celebration Week from September 19-23, 2011.

Be Healthy aims to help Novartis Group Company associates around the world embrace healthy lifestyles by providing opportunities for them to take control of their personal health and help prevent future health issues.

Novartis Group Company associates across 32 countries will participate in a new Novartis health and well-being initiative during the first Novartis Be Healthy Celebration Week from September 19-23, 2011. During the week, Novartis Group sites are offering many opportunities to help associates take control of their personal health. This includes providing information, activities and tips to promote health and help prevent future health issues.

Novartis presented an update on its long-term strategy, performance and vision for continued sustainable growth and gave an in-depth overview on the unique position and business model of the new Alcon Division. The company's diversified healthcare portfolio across high growth segments in healthcare as well as geographic distribution provides Novartis with strength and advantages to benefit from current trends in healthcare as well as protection from macroeconomic effects.

Today's best young talent will soon be changing the world. Novartis International Biotechnology Leadership Camp (BioCamp) offers top university students the opportunity to apply their bright minds to the trends and challenges of the biotechnology and healthcare industry and think like entrepreneurs. This year's BioCamp welcomed 60 participants to Novartis Headquarters in Basel, Switzerland, from August 29 to August 31, 2011.

Today, Novartis opened its eighth annual International Biotechnology Leadership Camp (BioCamp), a three-day seminar bringing biotechnology and business experts together with 60 selected students from leading international universities in 24 countries and territories. This year, Novartis highlighted the growing role of diversity in Group Companies worldwide to drive innovation in all aspects of the company including scientific research and development.

Future science and business leaders gathered at Novartis as some of the world's most talented students met and exchanged ideas at the International BioCamp.

Future science and business leaders gathered at Novartis as some of the world's most talented students met and exchanged ideas at the International Biotechnology Leadership Camp (BioCamp).

Dr. David Ross and Dr. Claire Harrison address the prognosis of myelofibrosis.

Dr. Alessandro Vannucchi explains how myeloproliferative neoplasms (MPNs) are diagnosed.

Dr. Claire Harrison explains myeloproliferative neoplasms (MPNs).

Novartis today held a groundbreaking ceremony to announce the start of construction of a pharmaceutical manufacturing plant in St. Petersburg, Russia. The construction of this facility represents the most significant Novartis investment in Russia to date. This facility will further expand the company's capabilities to produce and deliver both innovative pharmaceuticals and high-quality generics to Russian patients.

A woman diagnosed with multiple myeloma that has seriously impacted her bone health, joins a pet therapy program as a way to give back to others.

Gastrointestinal Stromal Tumors (GIST) are a rare, life-threatening form of cancer. Listen to four patient stories about living with the disease.

2011 GBC Business Action on Health Awards 'SMS for Life', a Novartis Malaria Initiative program, ranked #1 in Technology for Health category.

Novartis welcomes the decision to endorse the Pandemic Influenza Preparedness Framework (PIP Framework) at the Sixty-fourth World Health Assembly. The PIP Framework sets out the roles and commitments of different stakeholders, including the World Health Organization (WHO) and vaccine manufacturers, in pandemic preparedness.

Novartis provides unaudited restated and pro forma consolidated income statement data after the completion of the merger with Alcon, Inc.

Novartis ranks #6 among large companies for The Scientist Best Places to Work in Industry 2011.

Animal research is an important part of the research process when developing new treatments and medicines for patients. No one likes the idea, but as science has not evolved enough to make animal research unnecessary -- for now, this is how we make sure medicines are safe.

In 2001, Novartis AG and the World Health Organization (WHO) unveiled a unique 10-year alliance to provide a breakthrough medicine against malaria – without profit - for use by public health systems in developing countries.

Two African mothers struggle to find treatment for their daughters who are battling Malaria. Learn about the severity of the endemic and the complexity surrounding Malaria treatment and diagnosis in Africa.

Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Contributions from all businesses led to a good start in 2011, as we achieved 14% growth in the first quarter. We maintained our innovation momentum with new approvals for our multiple sclerosis treatment Gilenya and our eye care treatment Lucentis in the EU. Additionally, promising results of numerous clinical trials, including a Phase III study involving JAK inhibitor INC424, again showed the success of our novel approach to R&D. In April, we completed our merger with Alcon, the leading eye care business in the world, creating the second-largest business in the Novartis portfolio."

Together, Novartis and Alcon will hold competitive positions in highly complementary product areas and create an even stronger global leader in the dynamic eye care sector.

We have a great opportunity to redefine and shape the eye care industry, with the ultimate goal of preventing blindness and treating diseases and disorders of the eye.

Completion of the merger with Novartis strengthens Alcon's position as the global leader in eye care and increases the breadth of our eye care portfolio.

International BioCamp application process for students has begun. Apply today and get qualified for nomination to attend the 3 day event.

VetDogs: enriching life for disabled veterans. Watch the video on YouTube

Novartis committed to provide equivalent of more than USD 3 million in relief aid to Japan earthquakevictims

Diagnosing a rare autoinflammatory disease: CAPS. Watch the video on YouTube

Novartis and the World Health Organization (WHO) announced October 11 that they will extend their collaboration to end leprosy.

Novartis is pioneering medicines for neglected diseases, with institutes focusing solely on diseases for which research was virtually non-existent.

Novartis is leading industry efforts to fill a multi-billion-dollar gap in neglected disease R&D funding.

See Novartis Chairman Daniel Vasella, M.D., discuss the values and principles of the United Nations Global Compact on its 10th anniversary.

In a wide-ranging interview, Klaus Leisinger describes how Novartis embodies the principles of the United Nations Global Compact.

Keith Saveal, Head of Corporate Health, Safety and Environment & Business Continuity, recounts the evolution of the new UN Environmental Stewardship Strategy.

Eye care professionals are benefiting from an innovative new iPhone® application offering 'anytime, anywhere' access to high-quality educational resources.

On World Malaria Day, April 25, the international community highlights the campaign to provide effective control of this deadly disease.

People with multiple sclerosis (MS) face devastating uncertainty, not knowing how the disease will progress or disrupt their daily lives. But scientists are developing new diagnostic tools to aid treatment and ease the unpredictability for patients.

Novartis Vaccines and Diagnostics (NV&D) has developed a way to help parents, families and vaccine consumers track vaccinations using the iPhone ®.

Just as new medicines are improving the lives of patients fighting serious diseases, success in innovation is rejuvenating the portfolio of Novartis. Recently launched products grew to 16% of net sales for the Pharmaceuticals Division in 2009.

Novartis joins urgent relief efforts for victims of earthquake in Haiti offering aid in the form of financial support to relief organizations and donations of essential medicines.

In times of global financial uncertainty, the Novartis legal team takes an innovative approach – serving as both a protective guardian and a proactive partner to the business.

Today's best young minds will soon be changing the world. Novartis has created a unique global initiative encouraging top students to apply their intellects in the biotechnology industry – and to think like entrepreneurs.

A board of directors can restore confidence in the wake of a financial meltdown. On a panel at Yale University, Novartis General Counsel Thomas Werlen helps outline the qualities of a successful board.

More than 50 million American adults suffer from frequent heartburn. Painful symptoms can disrupt their lives. Now Novartis Consumer Health offers Prevacid®24HR, a new way to treat frequent heartburn over-the-counter.

Recent advances in science are enabling new treatments with greater efficacy and more convenient delivery. Novartis is investing significant resources to deliver these treatments to patients with MS.

An innovative new Novartis product brings fast, effective relief of pain and inflammation for pets. Onsior®, launched in Europe, is the first medication of its class for cats and dogs. The range of dosing options offer convenience for veterinarians and pet owners.

The once-dreaded disease leprosy is on the brink of elimination, but the fight goes on. Novartis commemorates 20 years of helping deliver free care, drugs and rehabilitation in India.

World leaders are focused on climate change and Novartis is, too. Our cutting-edge energy efficiency strategy is a driving long-term success for the environment and for our business.

Scientists who developed Novartis Coartem® and Glivec® receive 2009 "European Inventor of the Year" awards.

April 25 is World Malaria Day, an opportunity to reflect on the progress made in finding sustainable solutions for malaria.

With declining efficacy and resistance to existing sheep worm treatments on the rise, Novartis Animal Health worked together with sheep farmers and veterinarians to develop an unparalleled new treatment.

As World TB Day on March 24 raises global awareness, Novartis remains a committed partner in the struggle.

The challenges of developing products in rare diseases are many - but no obstacle for Novartis Development teams.

Novartis is working to expand its offering in emerging markets including Brazil, Russia, India and China.